SecBot SecBot
SECBOTREPLAY Home › Report › QTTB

QTTB · Q32 Bio announced the appointment of Dr

Q32 Bio Inc. · 8-K filed Sep 14, 2026 at 07:15 ET

At the news

NEUTRALIMPACT 3/10

8-K filed Sep 14, 2026 at 07:15 ET

Q32 Bio announced the appointment of Dr. José Trevejo as Chief Medical Officer and Dr. Ellie Hershberger as Chief Development Officer, both with strong late-stage development and regulatory backgrounds. The hires signal the company's transition toward a registration-directed program for bempikibart in alopecia areata, with a registrational trial expected in the first half of 2027. This is a routine executive appointment with no financial data or material business changes disclosed, making it a neutral event for traders.

  • Q32 Bio appointed Dr. José Trevejo as Chief Medical Officer and Dr. Ellie Hershberger as Chief Development Officer on September 14, 2026.
  • Dr. Trevejo previously served as CMO at Tarsus Pharmaceuticals, where he helped lead the FDA approval and launch of XDEMVY.
  • Dr. Hershberger previously served as CDO at Adagio Therapeutics (now Invivyd), contributing to its IPO that raised approximately $356 million in gross proceeds.
  • The company plans to advance bempikibart into a registration-directed program for severe or very severe alopecia areata in the first half of 2027.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access